S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB. (23rd June 2022) - Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; Choi, Y.; Balasubramanian, S.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; et al.